Maggie Stanislawski
Concepts (497)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 8 | 2023 | 697 | 2.040 |
Why?
| | Microbiota | 8 | 2023 | 762 | 1.670 |
Why?
| | Obesity | 9 | 2025 | 2992 | 1.080 |
Why?
| | Body Mass Index | 8 | 2025 | 2389 | 0.890 |
Why?
| | Life Style | 1 | 2025 | 490 | 0.780 |
Why?
| | Percutaneous Coronary Intervention | 11 | 2020 | 480 | 0.770 |
Why?
| | United States Department of Veterans Affairs | 14 | 2020 | 678 | 0.750 |
Why?
| | Behavior Therapy | 2 | 2021 | 264 | 0.740 |
Why?
| | Fatty Liver | 2 | 2021 | 243 | 0.690 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 85 | 0.680 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 351 | 0.610 |
Why?
| | Weight Loss | 2 | 2021 | 787 | 0.610 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 2531 | 0.600 |
Why?
| | Biostatistics | 1 | 2018 | 18 | 0.580 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 698 | 0.540 |
Why?
| | Pacemaker, Artificial | 4 | 2020 | 119 | 0.540 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2025 | 2189 | 0.540 |
Why?
| | Weight Gain | 2 | 2018 | 519 | 0.540 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 195 | 0.510 |
Why?
| | Insulin Resistance | 3 | 2024 | 1208 | 0.500 |
Why?
| | Bacteria | 3 | 2020 | 858 | 0.480 |
Why?
| | Phylogeny | 2 | 2018 | 904 | 0.470 |
Why?
| | Glucose Oxidase | 7 | 1994 | 26 | 0.460 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 279 | 0.450 |
Why?
| | Prosthesis-Related Infections | 4 | 2020 | 95 | 0.450 |
Why?
| | Pediatric Obesity | 2 | 2019 | 601 | 0.450 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 119 | 0.430 |
Why?
| | Liver | 9 | 2020 | 1943 | 0.420 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2018 | 549 | 0.420 |
Why?
| | Veterans Health | 4 | 2018 | 186 | 0.410 |
Why?
| | Feces | 4 | 2021 | 484 | 0.400 |
Why?
| | Phenotype | 6 | 2023 | 3196 | 0.400 |
Why?
| | Lactoperoxidase | 7 | 1994 | 7 | 0.390 |
Why?
| | Female | 46 | 2025 | 73304 | 0.360 |
Why?
| | Humans | 58 | 2025 | 137585 | 0.360 |
Why?
| | Risk Factors | 15 | 2023 | 10388 | 0.350 |
Why?
| | Peroxidases | 5 | 1993 | 34 | 0.350 |
Why?
| | Coronary Artery Bypass | 4 | 2017 | 234 | 0.350 |
Why?
| | Male | 39 | 2025 | 67762 | 0.340 |
Why?
| | Middle Aged | 29 | 2025 | 33479 | 0.340 |
Why?
| | Pregnancy | 7 | 2021 | 6763 | 0.330 |
Why?
| | Immunotoxins | 4 | 1990 | 55 | 0.320 |
Why?
| | Aged | 24 | 2025 | 23961 | 0.300 |
Why?
| | Dextrans | 5 | 1988 | 84 | 0.300 |
Why?
| | Veterans | 7 | 2018 | 1476 | 0.300 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2111 | 0.300 |
Why?
| | Immunoglobulin Idiotypes | 7 | 1988 | 27 | 0.290 |
Why?
| | Bifidobacterium | 2 | 2017 | 20 | 0.280 |
Why?
| | Myocardial Infarction | 6 | 2018 | 1046 | 0.280 |
Why?
| | Cohort Studies | 7 | 2025 | 5742 | 0.270 |
Why?
| | Multifactorial Inheritance | 2 | 2025 | 174 | 0.270 |
Why?
| | Coronary Angiography | 7 | 2020 | 317 | 0.260 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 255 | 0.240 |
Why?
| | Radial Artery | 2 | 2017 | 68 | 0.230 |
Why?
| | Defibrillators, Implantable | 2 | 2020 | 315 | 0.230 |
Why?
| | Time Factors | 11 | 2021 | 6828 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 539 | 0.220 |
Why?
| | Longevity | 1 | 2025 | 165 | 0.210 |
Why?
| | Diet | 3 | 2023 | 1278 | 0.210 |
Why?
| | T-Lymphocytes | 8 | 1995 | 1996 | 0.210 |
Why?
| | HIV-1 | 3 | 1995 | 864 | 0.210 |
Why?
| | Adult | 11 | 2025 | 37929 | 0.210 |
Why?
| | Risk Assessment | 4 | 2021 | 3457 | 0.210 |
Why?
| | Registries | 3 | 2019 | 2035 | 0.210 |
Why?
| | Logistic Models | 3 | 2025 | 2074 | 0.210 |
Why?
| | Child | 6 | 2021 | 21935 | 0.210 |
Why?
| | United States | 20 | 2020 | 14841 | 0.200 |
Why?
| | Plasmacytoma | 8 | 1989 | 16 | 0.200 |
Why?
| | Age Factors | 2 | 2021 | 3295 | 0.190 |
Why?
| | Metagenomics | 1 | 2023 | 169 | 0.190 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2020 | 617 | 0.190 |
Why?
| | Electronic Health Records | 2 | 2020 | 1069 | 0.190 |
Why?
| | Norway | 2 | 2018 | 43 | 0.190 |
Why?
| | Patient Identification Systems | 2 | 2019 | 16 | 0.180 |
Why?
| | Mothers | 2 | 2018 | 754 | 0.180 |
Why?
| | Mississippi | 1 | 2021 | 21 | 0.180 |
Why?
| | Acute Kidney Injury | 2 | 2020 | 815 | 0.180 |
Why?
| | Genome-Wide Association Study | 3 | 2025 | 1431 | 0.180 |
Why?
| | Proton Therapy | 1 | 2021 | 13 | 0.180 |
Why?
| | Diet, Reducing | 1 | 2021 | 89 | 0.180 |
Why?
| | Waist Circumference | 1 | 2021 | 143 | 0.180 |
Why?
| | Incidence | 4 | 2021 | 2804 | 0.170 |
Why?
| | Gardening | 1 | 2020 | 12 | 0.170 |
Why?
| | Adiposity | 1 | 2025 | 518 | 0.170 |
Why?
| | DNA, Bacterial | 2 | 2018 | 337 | 0.160 |
Why?
| | Caloric Restriction | 1 | 2021 | 124 | 0.160 |
Why?
| | Weight Reduction Programs | 1 | 2021 | 117 | 0.160 |
Why?
| | Mice, Inbred BALB C | 14 | 1989 | 1272 | 0.160 |
Why?
| | Western World | 1 | 2019 | 7 | 0.160 |
Why?
| | Fasting | 1 | 2021 | 281 | 0.160 |
Why?
| | Cardiac Catheterization | 3 | 2018 | 530 | 0.160 |
Why?
| | Precision Medicine | 1 | 2023 | 429 | 0.160 |
Why?
| | Machine Learning | 1 | 2024 | 493 | 0.160 |
Why?
| | Atherosclerosis | 1 | 2023 | 415 | 0.150 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 18 | 0.150 |
Why?
| | Proportional Hazards Models | 6 | 2018 | 1266 | 0.150 |
Why?
| | Fluid Therapy | 1 | 2020 | 147 | 0.150 |
Why?
| | Adolescent | 5 | 2021 | 21513 | 0.150 |
Why?
| | Perioperative Care | 1 | 2020 | 178 | 0.140 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.140 |
Why?
| | Prospective Studies | 3 | 2021 | 7604 | 0.140 |
Why?
| | Documentation | 1 | 2020 | 194 | 0.140 |
Why?
| | Drug Users | 1 | 2018 | 40 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1313 | 0.140 |
Why?
| | Vancomycin | 1 | 2018 | 84 | 0.140 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2017 | 847 | 0.140 |
Why?
| | Genes, rRNA | 1 | 2017 | 41 | 0.140 |
Why?
| | Streptococcus | 1 | 2017 | 28 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2018 | 73 | 0.140 |
Why?
| | Atherectomy, Coronary | 1 | 2017 | 10 | 0.140 |
Why?
| | Antibodies, Monoclonal | 10 | 2016 | 1430 | 0.140 |
Why?
| | Behavior, Addictive | 1 | 2018 | 81 | 0.140 |
Why?
| | Antiviral Agents | 2 | 1994 | 744 | 0.140 |
Why?
| | Coronary Stenosis | 1 | 2017 | 38 | 0.140 |
Why?
| | Homeostasis | 1 | 2021 | 621 | 0.140 |
Why?
| | Antibodies | 8 | 1983 | 410 | 0.140 |
Why?
| | History, 21st Century | 1 | 2018 | 213 | 0.140 |
Why?
| | Coronary Occlusion | 1 | 2017 | 19 | 0.130 |
Why?
| | Young Adult | 5 | 2021 | 13209 | 0.130 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 113 | 0.130 |
Why?
| | Contrast Media | 1 | 2020 | 467 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 181 | 0.130 |
Why?
| | Blood Transfusion | 2 | 2017 | 325 | 0.130 |
Why?
| | Data Collection | 1 | 2020 | 673 | 0.130 |
Why?
| | Psychological Trauma | 1 | 2017 | 55 | 0.130 |
Why?
| | Myeloma Proteins | 8 | 1984 | 16 | 0.130 |
Why?
| | Peroxidase | 2 | 1994 | 175 | 0.130 |
Why?
| | Binding Sites, Antibody | 6 | 1988 | 42 | 0.130 |
Why?
| | Population Surveillance | 1 | 2020 | 482 | 0.130 |
Why?
| | Infant, Newborn | 2 | 2018 | 6079 | 0.130 |
Why?
| | Program Evaluation | 3 | 2017 | 898 | 0.130 |
Why?
| | Antigens | 11 | 1979 | 357 | 0.130 |
Why?
| | Mice, Inbred Strains | 5 | 1987 | 409 | 0.130 |
Why?
| | Immunoglobulin G | 11 | 1988 | 893 | 0.130 |
Why?
| | Comorbidity | 2 | 2018 | 1622 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 219 | 0.120 |
Why?
| | Glucose | 1 | 2021 | 1020 | 0.120 |
Why?
| | Mycoplasma | 1 | 1995 | 5 | 0.120 |
Why?
| | Vascular Calcification | 1 | 2017 | 108 | 0.120 |
Why?
| | Femoral Artery | 1 | 2017 | 179 | 0.120 |
Why?
| | Mycoplasma Infections | 1 | 1995 | 16 | 0.120 |
Why?
| | Cross Reactions | 5 | 1988 | 133 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2426 | 0.120 |
Why?
| | Antibody Specificity | 10 | 1989 | 189 | 0.120 |
Why?
| | Medication Errors | 1 | 2016 | 95 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2020 | 635 | 0.120 |
Why?
| | Algorithms | 2 | 2020 | 1704 | 0.120 |
Why?
| | Hemorrhage | 2 | 2017 | 722 | 0.120 |
Why?
| | Treatment Outcome | 10 | 2019 | 10811 | 0.120 |
Why?
| | Research Report | 1 | 2016 | 83 | 0.120 |
Why?
| | Blood Glucose | 2 | 2024 | 2186 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1040 | 0.110 |
Why?
| | Social Determinants of Health | 1 | 2018 | 267 | 0.110 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.110 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 263 | 0.110 |
Why?
| | Saphenous Vein | 1 | 2014 | 35 | 0.110 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 261 | 0.110 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 83 | 0.110 |
Why?
| | Drug-Eluting Stents | 1 | 2014 | 81 | 0.110 |
Why?
| | Antimicrobial Stewardship | 1 | 2016 | 118 | 0.110 |
Why?
| | Infant | 2 | 2018 | 9465 | 0.110 |
Why?
| | Premature Birth | 1 | 2017 | 333 | 0.110 |
Why?
| | Hydrogen Peroxide | 1 | 1995 | 328 | 0.110 |
Why?
| | Stents | 2 | 2014 | 527 | 0.100 |
Why?
| | Methionine Sulfoximine | 2 | 1990 | 2 | 0.100 |
Why?
| | Lymphocyte Depletion | 2 | 1990 | 135 | 0.100 |
Why?
| | Patient Selection | 2 | 2016 | 696 | 0.100 |
Why?
| | Carmustine | 2 | 1990 | 50 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2017 | 435 | 0.100 |
Why?
| | Child, Preschool | 2 | 2018 | 11074 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7635 | 0.100 |
Why?
| | Overweight | 1 | 2017 | 558 | 0.100 |
Why?
| | Retrospective Studies | 10 | 2020 | 15657 | 0.100 |
Why?
| | Bone Marrow Transplantation | 2 | 1990 | 286 | 0.100 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 463 | 0.090 |
Why?
| | Databases, Factual | 4 | 2019 | 1357 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2018 | 530 | 0.090 |
Why?
| | Military Personnel | 1 | 2018 | 544 | 0.090 |
Why?
| | Immunoglobulin Allotypes | 3 | 1986 | 9 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1809 | 0.090 |
Why?
| | Nitrohydroxyiodophenylacetate | 2 | 1988 | 3 | 0.090 |
Why?
| | Bone Marrow | 2 | 1989 | 286 | 0.090 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 570 | 0.090 |
Why?
| | Coronary Disease | 1 | 2013 | 385 | 0.090 |
Why?
| | Sex Factors | 1 | 2017 | 2071 | 0.090 |
Why?
| | Rabbits | 15 | 1983 | 794 | 0.090 |
Why?
| | Hospitals, Veterans | 3 | 2018 | 252 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2017 | 654 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2691 | 0.090 |
Why?
| | Plasma Cells | 3 | 1976 | 71 | 0.080 |
Why?
| | Insulin | 1 | 2021 | 2409 | 0.080 |
Why?
| | Antigens, Neoplasm | 4 | 1990 | 319 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1101 | 0.080 |
Why?
| | Prevalence | 4 | 2018 | 2734 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3566 | 0.080 |
Why?
| | Antibodies, Anti-Idiotypic | 3 | 1985 | 59 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5472 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.080 |
Why?
| | Stroke | 1 | 2018 | 1120 | 0.080 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1988 | 20 | 0.080 |
Why?
| | Immunoglobulin Isotypes | 1 | 1988 | 34 | 0.080 |
Why?
| | Hospitalization | 2 | 2016 | 2199 | 0.080 |
Why?
| | Glycoproteins | 1 | 1990 | 342 | 0.070 |
Why?
| | Immune Sera | 11 | 1985 | 88 | 0.070 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 1986 | 83 | 0.070 |
Why?
| | Mice | 30 | 1989 | 17787 | 0.070 |
Why?
| | Immunoglobulin M | 6 | 1983 | 289 | 0.070 |
Why?
| | Animals | 42 | 2021 | 36940 | 0.070 |
Why?
| | Species Specificity | 2 | 1988 | 585 | 0.070 |
Why?
| | Adjuvants, Immunologic | 2 | 1988 | 226 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4565 | 0.070 |
Why?
| | Antibodies, Neoplasm | 2 | 1979 | 34 | 0.070 |
Why?
| | Nitrophenols | 1 | 1987 | 34 | 0.070 |
Why?
| | Cell Line | 6 | 1995 | 2847 | 0.070 |
Why?
| | Immunoglobulins | 7 | 1984 | 171 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2014 | 986 | 0.060 |
Why?
| | Receptors, Antigen, B-Cell | 5 | 1979 | 130 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 1986 | 90 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 1988 | 449 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 3 | 1983 | 80 | 0.060 |
Why?
| | Immunoelectrophoresis | 11 | 1976 | 16 | 0.060 |
Why?
| | Genes, MHC Class II | 2 | 1983 | 74 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 889 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5778 | 0.060 |
Why?
| | Anthropometry | 1 | 2025 | 213 | 0.060 |
Why?
| | Body Size | 1 | 2025 | 108 | 0.060 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1910 | 0.050 |
Why?
| | p-Azobenzenearsonate | 1 | 1983 | 4 | 0.050 |
Why?
| | B-Lymphocytes | 3 | 1979 | 847 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2021 | 2844 | 0.050 |
Why?
| | Azo Compounds | 1 | 1983 | 30 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 499 | 0.050 |
Why?
| | Mice, Inbred A | 3 | 1988 | 49 | 0.050 |
Why?
| | Lymphocytes | 3 | 1979 | 397 | 0.050 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 1979 | 20 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 1983 | 216 | 0.050 |
Why?
| | Adsorption | 4 | 1975 | 149 | 0.040 |
Why?
| | Kinetics | 6 | 1989 | 1670 | 0.040 |
Why?
| | Binding, Competitive | 4 | 1983 | 202 | 0.040 |
Why?
| | Diet Surveys | 1 | 2021 | 95 | 0.040 |
Why?
| | Radiometry | 1 | 2021 | 50 | 0.040 |
Why?
| | Microsomes | 4 | 1975 | 33 | 0.040 |
Why?
| | Lymph Nodes | 5 | 1985 | 491 | 0.040 |
Why?
| | Antibody Formation | 5 | 1987 | 298 | 0.040 |
Why?
| | Lipase | 1 | 2021 | 69 | 0.040 |
Why?
| | Immunoglobulin Fab Fragments | 3 | 2016 | 59 | 0.040 |
Why?
| | Neoplasms, Experimental | 4 | 1979 | 176 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1990 | 1692 | 0.040 |
Why?
| | HIV Infections | 1 | 1995 | 2836 | 0.040 |
Why?
| | Protons | 1 | 2021 | 89 | 0.040 |
Why?
| | Forehead | 1 | 2020 | 6 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 683 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 344 | 0.040 |
Why?
| | Patient Readmission | 2 | 2017 | 697 | 0.040 |
Why?
| | Buthionine Sulfoximine | 2 | 1990 | 9 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 88 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 152 | 0.040 |
Why?
| | Mouth | 1 | 2020 | 87 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 45 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 795 | 0.040 |
Why?
| | Multiple Myeloma | 3 | 1984 | 252 | 0.040 |
Why?
| | Gene-Environment Interaction | 1 | 2021 | 192 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2020 | 121 | 0.040 |
Why?
| | Immunoglobulin mu-Chains | 1 | 1979 | 8 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 145 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 740 | 0.040 |
Why?
| | Metabolomics | 1 | 2024 | 678 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 1979 | 47 | 0.040 |
Why?
| | Oceania | 1 | 2018 | 4 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2019 | 59 | 0.040 |
Why?
| | Child Behavior | 1 | 2021 | 248 | 0.040 |
Why?
| | Drug Synergism | 2 | 1990 | 382 | 0.040 |
Why?
| | Antigens, CD | 2 | 1993 | 521 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 96 | 0.040 |
Why?
| | Carrier Proteins | 1 | 1983 | 771 | 0.040 |
Why?
| | Quality Improvement | 2 | 2018 | 1178 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 849 | 0.040 |
Why?
| | Antigens, Surface | 1 | 1979 | 154 | 0.040 |
Why?
| | Teratoma | 1 | 1979 | 114 | 0.040 |
Why?
| | Cattle | 1 | 2021 | 984 | 0.040 |
Why?
| | Erythrocytes | 3 | 1989 | 700 | 0.040 |
Why?
| | Mice, Inbred C57BL | 9 | 1988 | 5757 | 0.040 |
Why?
| | Genes, Regulator | 1 | 1978 | 37 | 0.040 |
Why?
| | Skin | 1 | 2023 | 752 | 0.040 |
Why?
| | Peptides | 4 | 2016 | 985 | 0.040 |
Why?
| | Drug Prescriptions | 1 | 2020 | 245 | 0.040 |
Why?
| | Mice, Inbred C3H | 4 | 1988 | 269 | 0.040 |
Why?
| | Glutathione | 2 | 1990 | 356 | 0.040 |
Why?
| | North America | 1 | 2018 | 313 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1111 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2017 | 25 | 0.030 |
Why?
| | Europe | 1 | 2018 | 414 | 0.030 |
Why?
| | Punctures | 1 | 2017 | 40 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 351 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 1989 | 82 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 2017 | 45 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 827 | 0.030 |
Why?
| | Fibrosarcoma | 1 | 1976 | 22 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 406 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 307 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 190 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 90 | 0.030 |
Why?
| | Drug Labeling | 1 | 2016 | 39 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 746 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 234 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 956 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2016 | 57 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 416 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2021 | 530 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 762 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 331 | 0.030 |
Why?
| | Risk-Taking | 1 | 2018 | 348 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 6 | 1993 | 345 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 136 | 0.030 |
Why?
| | Fluorescence | 1 | 1995 | 160 | 0.030 |
Why?
| | Immunodiffusion | 7 | 1974 | 15 | 0.030 |
Why?
| | Cell Survival | 2 | 1990 | 1120 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2021 | 1164 | 0.030 |
Why?
| | Bioprosthesis | 1 | 2014 | 40 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 1994 | 30 | 0.030 |
Why?
| | HIV Core Protein p24 | 1 | 1994 | 31 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2014 | 76 | 0.030 |
Why?
| | Immune Tolerance | 3 | 1993 | 363 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1994 | 173 | 0.030 |
Why?
| | Catalase | 1 | 1994 | 130 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1972 | 0.030 |
Why?
| | Health Promotion | 1 | 2020 | 741 | 0.030 |
Why?
| | Metals | 1 | 2014 | 136 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2018 | 527 | 0.030 |
Why?
| | Inflammation | 1 | 2024 | 2837 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 362 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1509 | 0.030 |
Why?
| | Polystyrenes | 1 | 1993 | 35 | 0.030 |
Why?
| | CD8 Antigens | 1 | 1993 | 75 | 0.030 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 98 | 0.020 |
Why?
| | Lymphokines | 1 | 1993 | 131 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 314 | 0.020 |
Why?
| | Fibronectins | 1 | 1993 | 133 | 0.020 |
Why?
| | CD4 Antigens | 1 | 1993 | 141 | 0.020 |
Why?
| | Mental Health | 1 | 2018 | 726 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1710 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2031 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.020 |
Why?
| | Immunization, Passive | 2 | 1989 | 90 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 762 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 852 | 0.020 |
Why?
| | Acrylamides | 1 | 1972 | 57 | 0.020 |
Why?
| | Heparin | 1 | 1993 | 261 | 0.020 |
Why?
| | Epitopes | 4 | 1979 | 479 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1989 | 224 | 0.020 |
Why?
| | CD52 Antigen | 1 | 1990 | 4 | 0.020 |
Why?
| | Blood Proteins | 1 | 1973 | 252 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1793 | 0.020 |
Why?
| | Thymus Neoplasms | 1 | 1990 | 25 | 0.020 |
Why?
| | Thymoma | 1 | 1990 | 36 | 0.020 |
Why?
| | Mice, Inbred DBA | 2 | 1988 | 200 | 0.020 |
Why?
| | Isoelectric Focusing | 2 | 1988 | 34 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 385 | 0.020 |
Why?
| | Virus Replication | 1 | 1993 | 483 | 0.020 |
Why?
| | Proteins | 2 | 1993 | 1009 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2757 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1990 | 455 | 0.020 |
Why?
| | Dinitrophenols | 1 | 1988 | 8 | 0.020 |
Why?
| | Trinitrobenzenes | 1 | 1988 | 14 | 0.020 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 9 | 0.020 |
Why?
| | Rats, Nude | 1 | 1988 | 26 | 0.020 |
Why?
| | Esterases | 3 | 1968 | 14 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 1990 | 955 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 3 | 1975 | 55 | 0.020 |
Why?
| | Oxidative Stress | 1 | 1995 | 1317 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 1969 | 232 | 0.020 |
Why?
| | Hybridomas | 2 | 1993 | 237 | 0.020 |
Why?
| | Lymphoma | 1 | 1990 | 208 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 1989 | 316 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2020 | 2654 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 773 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1989 | 1092 | 0.020 |
Why?
| | Immunotherapy | 2 | 1989 | 641 | 0.020 |
Why?
| | Sheep | 4 | 1981 | 856 | 0.020 |
Why?
| | Rats | 7 | 1988 | 5647 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 1993 | 2139 | 0.020 |
Why?
| | Isoelectric Point | 1 | 1986 | 25 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1988 | 342 | 0.020 |
Why?
| | Electrophoresis | 4 | 1968 | 32 | 0.020 |
Why?
| | Chromium Radioisotopes | 1 | 1986 | 4 | 0.020 |
Why?
| | Heart Failure | 1 | 2020 | 2236 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1989 | 558 | 0.020 |
Why?
| | Abortion, Veterinary | 1 | 1986 | 2 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1969 | 362 | 0.020 |
Why?
| | Methods | 2 | 1979 | 65 | 0.020 |
Why?
| | Fetal Resorption | 1 | 1985 | 2 | 0.010 |
Why?
| | Fetal Death | 1 | 1985 | 55 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5131 | 0.010 |
Why?
| | Neoplasm Transplantation | 4 | 1984 | 257 | 0.010 |
Why?
| | Precipitin Tests | 2 | 1975 | 100 | 0.010 |
Why?
| | Cell Nucleus | 4 | 1968 | 620 | 0.010 |
Why?
| | Immunoglobulin Constant Regions | 1 | 1983 | 7 | 0.010 |
Why?
| | Phenylalanine | 1 | 1963 | 68 | 0.010 |
Why?
| | H-2 Antigens | 2 | 1986 | 115 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1990 | 4193 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1969 | 786 | 0.010 |
Why?
| | Interferon Type I | 1 | 1984 | 140 | 0.010 |
Why?
| | Acetates | 1 | 1963 | 99 | 0.010 |
Why?
| | Chromatography | 2 | 1973 | 24 | 0.010 |
Why?
| | Perfusion | 1 | 1963 | 213 | 0.010 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1983 | 137 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 49 | 0.010 |
Why?
| | Clone Cells | 2 | 1979 | 265 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1981 | 53 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1993 | 50 | 0.010 |
Why?
| | Research | 1 | 1963 | 451 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1979 | 157 | 0.010 |
Why?
| | Papain | 1 | 1979 | 3 | 0.010 |
Why?
| | Thymus Gland | 1 | 1979 | 312 | 0.010 |
Why?
| | Genes | 1 | 1978 | 230 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1978 | 297 | 0.010 |
Why?
| | Immunosorbent Techniques | 1 | 1976 | 21 | 0.010 |
Why?
| | Spleen | 3 | 1979 | 514 | 0.010 |
Why?
| | Sarcoma, Experimental | 1 | 1976 | 7 | 0.010 |
Why?
| | Mitochondria | 1 | 1963 | 948 | 0.010 |
Why?
| | Vaccination | 1 | 1985 | 1381 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1976 | 28 | 0.010 |
Why?
| | Glutaral | 1 | 1975 | 16 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1976 | 150 | 0.010 |
Why?
| | Antigens, Heterophile | 1 | 1975 | 5 | 0.010 |
Why?
| | Immunoassay | 1 | 1976 | 115 | 0.010 |
Why?
| | Cytoplasm | 1 | 1976 | 274 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1976 | 390 | 0.010 |
Why?
| | Cell Differentiation | 2 | 1974 | 1991 | 0.010 |
Why?
| | Antibody-Producing Cells | 1 | 1974 | 30 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1974 | 127 | 0.010 |
Why?
| | Globulins | 1 | 1973 | 1 | 0.010 |
Why?
| | Chloroform | 1 | 1973 | 4 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1976 | 433 | 0.010 |
Why?
| | Immunoglobulin Fragments | 1 | 1973 | 12 | 0.010 |
Why?
| | Thermolysin | 1 | 1993 | 4 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1973 | 7 | 0.010 |
Why?
| | Absorption | 1 | 1993 | 63 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1983 | 2607 | 0.010 |
Why?
| | CD57 Antigens | 1 | 1993 | 17 | 0.010 |
Why?
| | Chick Embryo | 1 | 1973 | 130 | 0.010 |
Why?
| | Hydrolysis | 1 | 1993 | 177 | 0.010 |
Why?
| | Solubility | 1 | 1973 | 245 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 137 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 1993 | 219 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1993 | 145 | 0.010 |
Why?
| | Chickens | 1 | 1973 | 191 | 0.010 |
Why?
| | Immunochemistry | 1 | 1972 | 14 | 0.010 |
Why?
| | Immunologic Techniques | 1 | 1972 | 40 | 0.010 |
Why?
| | Animals, Newborn | 1 | 1974 | 844 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1972 | 180 | 0.010 |
Why?
| | Cell Membrane | 1 | 1975 | 738 | 0.010 |
Why?
| | Muramidase | 1 | 1972 | 78 | 0.010 |
Why?
| | Leukocytes | 1 | 1973 | 311 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1972 | 148 | 0.010 |
Why?
| | Cholinesterases | 2 | 1968 | 10 | 0.010 |
Why?
| | Deoxyribonucleases | 2 | 1968 | 24 | 0.010 |
Why?
| | Aldehydes | 1 | 1972 | 145 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 2 | 1968 | 122 | 0.010 |
Why?
| | Lipoproteins | 1 | 1971 | 168 | 0.010 |
Why?
| | Blotting, Western | 1 | 1993 | 1226 | 0.010 |
Why?
| | Protein Conformation | 1 | 1993 | 934 | 0.010 |
Why?
| | Endoplasmic Reticulum | 1 | 1971 | 265 | 0.000 |
Why?
| | Ethanol | 1 | 1973 | 608 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1993 | 2900 | 0.000 |
Why?
| | Protein Binding | 1 | 1993 | 2224 | 0.000 |
Why?
| | Liver Diseases | 1 | 1969 | 315 | 0.000 |
Why?
| | Enzymes | 1 | 1966 | 67 | 0.000 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1986 | 173 | 0.000 |
Why?
| | Fetal Viability | 1 | 1985 | 3 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1985 | 54 | 0.000 |
Why?
| | Genetic Variation | 1 | 1970 | 991 | 0.000 |
Why?
| | Pronase | 1 | 1981 | 5 | 0.000 |
Why?
| | Rosette Formation | 1 | 1981 | 16 | 0.000 |
Why?
| | Trypsin | 1 | 1981 | 77 | 0.000 |
Why?
| | Contact Inhibition | 2 | 1970 | 5 | 0.000 |
Why?
| | Culture Techniques | 2 | 1970 | 81 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1985 | 1142 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1985 | 718 | 0.000 |
Why?
| | Ascitic Fluid | 1 | 1979 | 15 | 0.000 |
Why?
| | Microscopy, Electron | 2 | 1970 | 443 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 367 | 0.000 |
Why?
| | Epithelium | 2 | 1970 | 313 | 0.000 |
Why?
| | beta-Galactosidase | 1 | 1979 | 78 | 0.000 |
Why?
| | Cell Cycle | 1 | 1981 | 601 | 0.000 |
Why?
| | Placenta | 1 | 1985 | 750 | 0.000 |
Why?
| | Fibroblasts | 2 | 1970 | 996 | 0.000 |
Why?
| | Neuraminic Acids | 1 | 1972 | 1 | 0.000 |
Why?
| | Densitometry | 1 | 1972 | 36 | 0.000 |
Why?
| | Neuraminidase | 1 | 1972 | 24 | 0.000 |
Why?
| | Vibrio cholerae | 1 | 1972 | 13 | 0.000 |
Why?
| | Ultracentrifugation | 1 | 1972 | 52 | 0.000 |
Why?
| | Microsomes, Liver | 1 | 1972 | 86 | 0.000 |
Why?
| | Leukemia Virus, Murine | 1 | 1970 | 18 | 0.000 |
Why?
| | Intestines | 1 | 1972 | 357 | 0.000 |
Why?
|
|
Stanislawski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|